Veracyte Seeks To Raise $400M To Fund Decipher Biosciences Deal

by Vandana Singh, Benzinga Editor

February 4, 2021 6:13 AM | 1 min read | Make a Comment

Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.
Veracyte will use proceeds to finance its Decipher Biosciences acquisition announced yesterday and working capital and other general corporate purposes.
Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
Price Action: VCYT closed 13.47% higher at $73.79 on Wednesday.

Posted In: Biotech M&A News Offerings General

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.